Dyadic Reports Third Quarter 2021 Financial Results and Highlights Recent Company Progress

by B2i | Nov 10, 2021 | Press Releases

•COVID-19 vaccine candidate, DYAI-100, continues to advance towards first-in-human clinical trial to validate C1 produced proteins are safe in humans and further accelerate global C1 platform adoption •Five non-COVID-19 infectious disease monoclonal...

Dyadic Appoints Chief Business Officer to Executive Leadership Team

by B2i | Nov 9, 2021 | Press Releases

JUPITER, Fla., Nov. 09, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic to Report Third Quarter 2021 Financial Results on Wednesday, November 10, 2021

by B2i | Oct 27, 2021 | Press Releases

JUPITER, Fla., Oct. 27, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on further improving, applying and...

Dyadic to Present at H.C. Wainwright 23rd Annual Global Investment Conference

by B2i | Sep 10, 2021 | Press Releases

JUPITER, Fla., Sept. 10, 2021 — Dyadic International, Inc. (“Dyadic”, “we”, “us”, “our”, or the “Company”) (NASDAQ:DYAI), a global biotechnology company focused on further improving, applying, and...

Dyadic Reports Second Quarter 2021 Financial Results and Highlights Recent Company Progress

by B2i | Aug 12, 2021 | Press Releases

Executed binding term sheet with Sorrento Therapeutics (Nasdaq:SRNE) to outlicense C1 protein production platform for the development and commercialization of vaccines, therapeutic antibodies, protein therapeutics, and diagnostics for coronaviruses, including...